TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9023301

Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Transdermal GTN
Number of subjects: 38
Study: 8323380

Group type: EXPERIMENTAL
Intervention: Intervention not specified, but involves treatment for rheumatoid arthritis with a focus on radiological progression.
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control not specified, but implies a comparison group in the trial.
Number of subjects: 153
Study: 3701668

Group type: EXPERIMENTAL
Intervention: Enuresis wire mesh
Number of subjects: 7

Group type: COMPARATOR
Intervention: No enuresis wire mesh (control)
Number of subjects: 7
Study: 31241204

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Commitment to PA
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Model prediction
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Social support and options for PA
Number of subjects: 517
Study: 28040448

Group type: EXPERIMENTAL
Intervention: Belladonna and opium rectal suppositories (16.2/60 mg) administered rectally immediately after surgery and every 8 hours for a total of 3 doses.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo suppositories administered rectally immediately after surgery and every 8 hours for a total of 3 doses.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Belladonna and opium rectal suppositories
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo suppositories
Number of subjects: 90
Study: 25270958

Group type: EXPERIMENTAL
Intervention: Etanercept (0.4 mg/kg twice weekly for 8 doses) plus systemic corticosteroids (2.0 mg/kg/day)
Number of subjects: 39
Study: 24154773

Group type: EXPERIMENTAL
Intervention: CO₂ insufflation
Number of subjects: 205

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 205
Study: 21285990

Group type: EXPERIMENTAL
Intervention: Dexamethasone, Aspirin, and immediate addition of Diethylstilbestrol (DAiS)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Dexamethasone, Aspirin, and deferred addition of Diethylstilbestrol (DAdS)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Dexamethasone (before adding Diethylstilbestrol)
Number of subjects: 270
Study: 20183665

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Combination of Fluoxetine and CBT
Number of subjects: 439

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439
Study: 16395727

Group type: COMPARATOR
Intervention: Granulocytapheresis (5 sessions at one session/week over 5 consecutive weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Granulocytapheresis (for subgroup with duration of BD >= 5 years)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Granulocytapheresis (for subgroup with duration of BD < 5 years)
Number of subjects: 14
Study: 14707831

Group type: EXPERIMENTAL
Intervention: lanreotide
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 11938807

Group type: EXPERIMENTAL
Intervention: QRBCAD medication (Group B)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Radiotherapy without QRBCAD (Group A)
Number of subjects: 58
Study: 8704697

Group type: EXPERIMENTAL
Intervention: Peripheral stem cell transplantation
Number of subjects: 71

Group type: COMPARATOR
Intervention: Autologous BMT
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Low PC pre-chemotherapy
Number of subjects: 71
Study: 1513973

Group type: EXPERIMENTAL
Intervention: Long-term oxygen therapy (LTOT)
Number of subjects: 269

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 269
Study: 6432084

Group type: EXPERIMENTAL
Intervention: Dihydroergostin (DE‐145) 2 mg intravenous administration
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study: 30791889

Group type: COMPARATOR
Intervention: Arm A: Stupp protocol (EBRT 60 Gy + 2 cm margin with concomitant temozolomide (TMZ) and 6 months of TMZ maintenance)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Arm B: Stupp protocol with additional simultaneous integrated boost of IMRT of 72Gy/2.4Gy delivered on MR spectroscopic imaging metabolic volumes of CHO/NAA > 2 and contrast-enhancing lesions or resection cavity
Number of subjects: 220
Study: 29246729

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 119

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 119
Study: 27116647

Group type: COMPARATOR
Intervention: Mental work + rest (MW + R)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Mental work + exercise (MW + E)
Number of subjects: 38
Study: 25169846

Group type: EXPERIMENTAL
Intervention: Clarithromycin plus neuraminidase inhibitors
Number of subjects: 63

Group type: COMPARATOR
Intervention: Neuraminidase inhibitors (control group)
Number of subjects: 63
Study: 22915298

Group type: EXPERIMENTAL
Intervention: Vitamin B-12 supplementation (1 mg i.m. single dose then 500 μg/d orally for 3 months)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 20428914

Group type: EXPERIMENTAL
Intervention: Curative resection of colon cancer via minilaparotomy utilizing specific instruments (North‐bridge retractor system)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Curative resection of colon cancer via minilaparotomy without utilizing specific instruments
Number of subjects: 167
Study: 18048435

Group type: COMPARATOR
Intervention: Placebo (LHTL1 group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: G lucidum 10 capsules/day (LHTL2 group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: G lucidum 20 capsules/day (LHTL3 group)
Number of subjects: 40
Study: 16037127

Group type: EXPERIMENTAL
Intervention: Water drink (7.5 ml/kg body wt)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Physiological saline (0.9%)
Number of subjects: 9
Study: 11966935

Group type: EXPERIMENTAL
Intervention: Topical application of n-6 polyunsaturated fatty acids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical application of n-3 polyunsaturated fatty acids
Number of subjects: 0
Study: 10573494

Group type: EXPERIMENTAL
Intervention: Diet plus lovastatin or simvastatin (statin group, n = 23)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Diet alone (diet group, n = 20)
Number of subjects: 43
Study: 8918492

Group type: EXPERIMENTAL
Intervention: 5-FU (700 mg/m2/d), FA (300 mg/m2/d), and L-OHP (25 mg/m2/d) administered daily for 4 days every 14 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 5-FU dose intensity > 1,400 mg/m2/wk over four courses
Number of subjects: 50

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 50
Study: 1986658

Group type: EXPERIMENTAL
Intervention: Propofol 3 mg.kg‐1
Number of subjects: 21

Group type: COMPARATOR
Intervention: Propofol 5 mg.kg‐1
Number of subjects: 21

Group type: COMPARATOR
Intervention: Thiopental 5‐7 mg.kg‐1
Number of subjects: 21
Study: 6642069

Group type: EXPERIMENTAL
Intervention: 500 mg of enteric-coated erythromycin base (Ery-Max) administered twice daily for 10 days
Number of subjects: 220

Group type: COMPARATOR
Intervention: 250 mg of enteric-coated erythromycin base (Ery-Max) administered four times daily for 10 days
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Treatment with enteric-coated erythromycin base (Ery-Max)
Number of subjects: 220
Study: 30156338

Group type: EXPERIMENTAL
Intervention: Oronasal mask with auto-titrating positive airway pressure (APAP) for 2 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nasal mask with auto-titrating positive airway pressure (APAP) for 2 weeks
Number of subjects: 60
Study: 30350405

Group type: EXPERIMENTAL
Intervention: Respiratory muscle endurance training (RMET)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 16
Study: 26897389

Group type: EXPERIMENTAL
Intervention: SMART regimen (budesonide/formoterol 200/6-µg metered dose inhaler for maintenance and reliever therapy)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Standard regimen (salbutamol 100 µg 1-2 actuations for symptom relief)
Number of subjects: 303
Study: 25111218

Group type: COMPARATOR
Intervention: ACD
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sevoflurane with ACD
Number of subjects: 15
Study: 23917766

Group type: EXPERIMENTAL
Intervention: Early mobilization protocol (n=14)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional physical therapy (control group, n=14)
Number of subjects: 59
Study: 19575501

Group type: EXPERIMENTAL
Intervention: Esophagogastric anterior wall end-to-side anastomosis combined with pyloroplasty (EA group)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Esophagogastric posterior wall end-to-side anastomosis (EP group)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Esophagogastric end-to-end anastomosis (EE group)
Number of subjects: 149
Study: 17498016

Group type: EXPERIMENTAL
Intervention: Rectal paracetamol (20‐25 mg x kg(‐1)) at the third hour
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Rectal paracetamol (20‐25 mg x kg(‐1)) at the fourth hour
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control group (no analgesic until pain score of 5 or higher)
Number of subjects: 202
Study: 14634860

Group type: EXPERIMENTAL
Intervention: Maintenance iron therapy (6 mg/kg per month)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent iron therapy (14.4 mg/kg per month)
Number of subjects: 0
Study: 10852322

Group type: EXPERIMENTAL
Intervention: Intramedullary nailing
Number of subjects: 53

Group type: COMPARATOR
Intervention: Plaster cast
Number of subjects: 53
Study: 9327818

Group type: EXPERIMENTAL
Intervention: Home exercise program (n = 14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (n = 14)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Individuals with CPN
Number of subjects: 28
Study: 8403132

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (SAB) with plain 0.5% bupivacaine (15 mg) and 0.2 mg epinephrine added
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lumbar epidural anaesthesia (EA) with 2% mepivacaine and 1:200,000 epinephrine added
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia (AEA) with the same solution alkalinized with bicarbonate
Number of subjects: 60
Study: 3533469

Group type: EXPERIMENTAL
Intervention: Intravenous fluorouracil (5‐FU) in two courses, four and eight weeks after surgery
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (no chemotherapy)
Number of subjects: 128
Study: 3042643

Group type: EXPERIMENTAL
Intervention: Ketoprofen gel
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Etofenamate gel
Number of subjects: 36
Study: 30753901

Group type: EXPERIMENTAL
Intervention: Lateral position on the same side of the fetal spine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obstetrical forceps
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manual rotation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thierry's spatulas
Number of subjects: 0
Study: 28639564

Group type: EXPERIMENTAL
Intervention: 12-session executive skill training program
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 38
Study: 25036283

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 128

Group type: COMPARATOR
Intervention: Palpation
Number of subjects: 128
Study: 22771145

Group type: EXPERIMENTAL
Intervention: 12-step facilitation treatment
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Pre-morbid functioning (FrSBe-Total)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Current functioning (FrSBe-Total)
Number of subjects: 180
Study: 21647654

Group type: EXPERIMENTAL
Intervention: Rifaximin 1,200 mg daily for 10 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 50
Study: 17909084

Group type: EXPERIMENTAL
Intervention: pioglitazone (PIO group; 45 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ramipril (RAM group; 10 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo (PLC group)
Number of subjects: 30
Study: 15901651

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging and computational surface‐based methods to encode hemispheric differences in callosal thickness.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Examination of parasagittal callosal asymmetries within each gender.
Number of subjects: 0
Study: 12760989

Group type: EXPERIMENTAL
Intervention: Remifentanil (2 and 4 ng/mL)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Remifentanil (1 to 100 micro g/h)
Number of subjects: 24
Study: 10847536

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) treatment with a resorbable polylactic acid (PLA) barrier
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control site (no barrier placed)
Number of subjects: 20
Study: 9171787

Group type: EXPERIMENTAL
Intervention: Breath-hold magnetic resonance cholangio-pancreatography (MRCP)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangio-pancreatography (ERCP)
Number of subjects: 19
Study: 8256770

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide and hydrocortisone acetate with tamoxifen continuation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aminoglutethimide and hydrocortisone acetate without tamoxifen continuation
Number of subjects: 0
Study: 3519383

Group type: EXPERIMENTAL
Intervention: Defibrotide
Number of subjects: 52

Group type: COMPARATOR
Intervention: Dipyridamole
Number of subjects: 52
Study: 30104114

Group type: EXPERIMENTAL
Intervention: BRV-PV
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Rotarix
Number of subjects: 1500
Study: 26508503

Group type: EXPERIMENTAL
Intervention: Iguratimod plus methotrexate (MTX)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Iguratimod (25 mg, twice daily, orally)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Methotrexate (weekly dose of 10 mg, orally)
Number of subjects: 131
Study: 24838085

Group type: EXPERIMENTAL
Intervention: Trained healthcare personnel
Number of subjects: 111

Group type: COMPARATOR
Intervention: Trained nurses
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Trained nurse aids
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Trained housekeepers
Number of subjects: 111
Study: 22840618

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Chinese Chan-based Dejian Mind-Body Intervention (DMBI)
Number of subjects: 75
Study: 20138384

Group type: EXPERIMENTAL
Intervention: Personalized exercise prescription by a physical therapist over a 2‐y intervention period
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 74
Study: 18702903

Group type: EXPERIMENTAL
Intervention: PARI sinus nebulizer (3 minutes of nebulization bilaterally)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nasal douching with a 200‐mL nasal irrigation bottle (one standardized squeeze bilaterally)
Number of subjects: 14
Study: 15888510

Group type: EXPERIMENTAL
Intervention: lorazepam (1 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: lorazepam (2 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: THREAT condition
Number of subjects: 18
Study: 12810142

Group type: EXPERIMENTAL
Intervention: Buprenorphine 1 mg
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Buprenorphine 3 mg
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Buprenorphine 8 mg
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Methadone 30 mg
Number of subjects: 164
Study: 10661397

Group type: EXPERIMENTAL
Intervention: Alternative analysis methods for randomized cluster trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Typical Pearson's chi2 analysis
Number of subjects: 0
Study: 9181278

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 1292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: All treatments (including placebo)
Number of subjects: 1292
Study: 8246650

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 3464721

Group type: EXPERIMENTAL
Intervention: Strontium glass filled composite (Profile)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Microfilled composite (Estic MF)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Macrofilled composite (Adaptic Radiopaque)
Number of subjects: 49

Group type: COMPARATOR
Intervention: High copper amalgam (Dispersalloy)
Number of subjects: 49
Study: 29772609

Group type: EXPERIMENTAL
Intervention: Standardized electronic message four times/week for 6 months postpartum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Messages and option to request a call from a nurse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 27939846

Group type: EXPERIMENTAL
Intervention: MPathic-VR
Number of subjects: 421

Group type: COMPARATOR
Intervention: Computer-based learning
Number of subjects: 421
Study: 26700832

Group type: EXPERIMENTAL
Intervention: ACC/AHA risk-based approach
Number of subjects: 37892

Group type: COMPARATOR
Intervention: Trial-based approach
Number of subjects: 37892

Group type: COMPARATOR
Intervention: Hybrid approach
Number of subjects: 37892
Study: 23560515

Group type: EXPERIMENTAL
Intervention: Guided Care
Number of subjects: 14

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 14
Study: 21051087

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 69
Study: 18566340

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (standard medical care)
Number of subjects: 127
Study: 16641430

Group type: EXPERIMENTAL
Intervention: FTC plus CLV (200 mg FTC QD + 10 mg CLV QD)
Number of subjects: 163

Group type: COMPARATOR
Intervention: FTC alone (200 mg FTC QD + placebo)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: FTC plus CLV
Number of subjects: 163

Group type: COMPARATOR
Intervention: FTC alone
Number of subjects: 163
Study: 12548251

Group type: EXPERIMENTAL
Intervention: 3-day drainage bag change
Number of subjects: 153

Group type: COMPARATOR
Intervention: No change regimen
Number of subjects: 153
Study: 10370615

Group type: EXPERIMENTAL
Intervention: Stop-flow thoracic perfusion with systemic chemotherapy and inhalation IL-2 immunotherapy (Group B)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Stop-flow thoracic perfusion with systemic chemotherapy without inhalation IL-2 immunotherapy (Group A)
Number of subjects: 67
Study: 8670532

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg bd
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 1667754

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 1 g infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7198873

Group type: EXPERIMENTAL
Intervention: 0.25% dibucaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.5% tetracaine
Number of subjects: 30
Study: 31377278

Group type: EXPERIMENTAL
Intervention: Micro-Stent implantation plus phacoemulsification
Number of subjects: 349

Group type: COMPARATOR
Intervention: Phacoemulsification alone (Control)
Number of subjects: 349
Study: 28257146

Group type: EXPERIMENTAL
Intervention: Neurofeedback (NFB) group
Number of subjects: 62

Group type: COMPARATOR
Intervention: Wait-list control (WLC) group
Number of subjects: 62
Study: 26340544

Group type: EXPERIMENTAL
Intervention: MVPCI
Number of subjects: 543434
Study: 23819882

Group type: EXPERIMENTAL
Intervention: Midwifery continuity of care through pregnancy, labour, birth and early postnatal care.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard hospital care from different midwives through pregnancy, labour, birth and early postnatal care.
Number of subjects: 0
Study: 22963588

Group type: EXPERIMENTAL
Intervention: Exercise on Prescription (EoP) - 18 sessions of supervised physical activity
Number of subjects: 514

Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Exercise on Prescription (EoP)
Number of subjects: 514
Study: 20017866

Group type: EXPERIMENTAL
Intervention: Caudal block
Number of subjects: 38

Group type: COMPARATOR
Intervention: i.v. fentanyl
Number of subjects: 38
Study: 17565168

Group type: EXPERIMENTAL
Intervention: Guided action training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guided attention training
Number of subjects: 0
Study: 15450646

Group type: EXPERIMENTAL
Intervention: Relational Psychotherapy Mothers' Group (RPMG)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard Drug Counseling (DC)
Number of subjects: 52
Study: 11380069

Group type: EXPERIMENTAL
Intervention: Test isosorbide dinitrate sublingual tablet (5 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference isosorbide dinitrate sublingual tablet (5 mg)
Number of subjects: 20
Study: 9530481

Group type: EXPERIMENTAL
Intervention: Combined application of pulse oximetry and capnometry
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard monitoring without pulse oximetry and capnometry
Number of subjects: 48
Study: 8527291

Group type: EXPERIMENTAL
Intervention: 30 micrograms PGE1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 60 micrograms PGE1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 120 micrograms PGE1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30-120 micrograms PGE1
Number of subjects: 12
Study: 2233904

Group type: EXPERIMENTAL
Intervention: H. influenzae type b capsular polysaccharide-diphtheria toxoid conjugate vaccine (PRP-D) administered at ages 3, 4, 6, and 14 to 18 months
Number of subjects: 114000

Group type: COMPARATOR
Intervention: Control group receiving the same vaccine at the age of 24 months
Number of subjects: 114000

Group type: EXPERIMENTAL
Intervention: H. influenzae type b capsular polysaccharide-diphtheria toxoid conjugate vaccine (PRP-D)
Number of subjects: 114000